Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Direxion Daily CSI China Internet Bull 2X Shares (CWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Direxion Daily CSI China Internet Bull 2X Shares — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.76 (market cap $9.43B), while Direxion Daily CSI China Internet Bull 2X Shares trades at $23.48. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| BIO | CWEB | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $356.25 | $60.13 |
52-Week Low | $241.71 | $17.70 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
CWEB trades at $23.74, down 9.94% over 24 hours, with technical indicators showing mixed signals—moving averages are bearish while oscillators are neutral. The stock exhibits a bullish overall signal, supported by strong ADX readings indicating a trending market. Recent news highlights potential renewed interest in China growth stocks following a related IPO, which could benefit CWEB.
The outlook for CWEB hinges on positive sentiment around China equities, but risks include market volatility and geopolitical factors. Key support is at $24, with resistance at $25. Investors should monitor earnings reports for fundamental validation, as current financial ratios are unavailable, limiting valuation clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →
